INFINITY PHARMACEUTICALS, INC.
INFI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INFI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2023.
Tracking 1 pipeline candidate · 3 clinical trials for INFINITY PHARMACEUTICALS, INC..
Run INFINITY PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available INFINITY PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
6.9 months
OCF -$8M · Net income -$10M
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Frequently asked questions
What is INFINITY PHARMACEUTICALS, INC.'s lead drug candidate?
INFINITY PHARMACEUTICALS, INC.'s most advanced tracked candidate is eganelisib (Phase 2) for solid tumors.
What therapeutic areas does INFINITY PHARMACEUTICALS, INC. focus on?
INFINITY PHARMACEUTICALS, INC. develops therapies across Oncology, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.